Approximately 18% of the global cancer burden has been attributed to infectious agents, with estimates ranging from 7% in developed countries to about 22% in developing countries.
The International Agency for Research on Cancer (IARC) has identified seven major infectious agents as carcinogenic: hepatitis B virus (HBV), hepatitis C virus (HCV), certain strains of the human papillomavirus (HPV), Epstein-Barr virus (EBV), human immunodeficiency virus type-1 (HIV-1), human T-cell lymphotropic virus type-1 (HTLV-1), and the gram-negative bacterium Helicobacter pylori (H. pylori) (2) . The prevalence of these infectious agents is shown in Table I . Although many of these infectious agents (e.g., HPV, EBV, and H. pylori) are highly prevalent in the world, most infected individuals do not develop cancer and may remain lifelong carriers. It is important to note that malignancies associated with infectious agents result from prolonged latency and/or co-infections in the host (4) . Other cofactors in the host-such as genetic susceptibility, age, the robustness of the immune system, dietary habits, and environmental factors-also are required for these infections to cause cancer (5) .
Co-infections that alter the immune system can increase the host's susceptibility to cancer and often are important cofactors in cancer causation. Several studies have highlighted the impact of co-infections in carcinogenesis (6) (7) (8) (9) (10) (11) . Co-infections also can affect response to cancer treatment. In HPVpositive individuals, previous exposure to infectious agents such as Chlamydia trachomatis (CT) and herpes simplex virus type-2 (HSV-2) increases the risk for cervical cancer (12) . Studies also have shown that individuals who test positive for multiple strains of HPV have a lower response to cancer treatments (13, 14) . Similarly, there is evidence that Plasmodium falciparum (P. falciparum)-mediated malaria contributes incrementally to the development of EBV-associated endemic Burkitt lymphoma (BL) (15) . These studies further support the growing understanding that having multiple infections provides an opening for the development of various cancers.
HIV-related malignancies constitute a large component of co-infections that contribute to carcinogenesis (16, 17) .
Among HIV-positive individuals, co-infection with oncogenic viruses, including EBV, HBV, HCV, Kaposi sarcomaassociated herpesvirus (KSHV), and HPV cause significant cancer-related morbidity and mortality (18, 19) . Many studies have demonstrated that these viruses interact with HIV in unique ways to predispose HIV-positive individuals to malignant diseases (2, 16, (20) (21) (22) (23) (24) .
Co-infections can lead to gene alterations in the microbes of the host and can differentially affect susceptibility to certain diseases including cancer (25, 26) . Infections with multiple pathogenic agents often cause chronic inflammation in tissues and organs that may lead to the initiation of cancer. Co-infections that have been associated with common malignant infections are shown in Table II . Several studies have shown a correlation between microbial load and cancer manifestation (1, (27) (28) (29) . Although most studies have shown that HBV and HCV co-infection increases the risk of hepatocellular carcinoma (HCC) (18, 30, 31) , a recent study on the additive effect of HBV and HCV co-infection in HCC suggests that the risk of developing HCC is not significantly greater with HBV/HCV co-infection than with HBV/HCV mono-infection (32) .
Multiple malignant infections are a major threat to transplant patients. The increased risk of infection post-transplant is attributed to longer graft survival and age of both the organ donor and recipient, as age is an important factor in the development of malignancies that are associated with infectious agents (33) . The introduction of potent immunosuppressive therapy and the presence of latent infections in donors and recipients pose additional challenges in transplantation medicine (34) . Post-transplant lymphoproliferative disorders (PTLD) are a group of lymphoproliferative diseases that occur in transplant patients, ranging from selflimited lymphoproliferation to aggressive lymphomas (35) . About 50%-80% of PTLD cases are EBV-positive, with EBV-associated lymphoma being the second most common malignancy in organ transplant recipients (27, 35) . Other viruses that infect immunocompromised patients, such as HBV, HCV, and HPV, have been linked to the development of cancer in transplant patients as well (36, 37) .
Not only are multiparasitism and co-infections a major public health concern worldwide, but they also are a causative agent for several cancers. The significant impact of cancer-associated chronic infections on the global cancer burden emphasizes the need to develop better technologies for prevention and treatment. Preventing infectious agents is required not only to prevent cancer morbidity and mortality, but also to prevent the development of cancer-related diseases.
Recent advances in the areas of molecular and clinical research have expanded our understanding of the role of malignant infections but have yet to identify the mechanism of carcinogenesis (38). Epidemiologic studies have helped to identify key determinants such as risk factors and cofactors that modify the effect of these infectious agents (39) . This article highlights the role of co-infections in carcinogenesis and identifies available treatments for these malignant infections (Table III) .
Examples of Selected Cancer-associated Infectious Agents
Helicobacter Pylori H. pylori is a gram-negative bacterium found on the luminal surface of the gastric epithelium. The prevalence of H. pylori infection varies by geographic region, with the overall prevalence estimated to be 80% in developing countries and 50% in developed countries (2, 40, 41) . Infection usually occurs during childhood by either the oral-oral or fecal-oral routes, and the pathogen can persist indefinitely if left untreated (42) . Based on epidemiologic and molecular studies, the IARC classified H. pylori as a carcinogen in 1994 (43) .
H. pylori infection is associated with two gastrointestinal cancers-noncardiac gastric adenocarcinoma and gastric non-Hodgkin lymphoma or mucosa-associated lymphoidtissue (MALT) lymphoma-and accounts for approximately three-quarters of the cases of each of these diseases worldwide (44) (45) (46) . The risk of either of these cancers is approximately six times higher for H. pylori-infected individuals than for their uninfected counterparts. The epidemiology of H. pylori infection typically follows a birth-cohort model: older individuals (infected decades ago) frequently carry the bacterium, whereas children rarely do (47) .
Because only a subset of H. pylori-infected individuals develops gastrointestinal disease and gastric cancer, differential pathogenic studies have identified some strains of H. pylori that are more virulent (48, 49) . Because of their virulence factors, when injected into host cells, these virulent strains can affect epithelial cell function (50, 51) . One of the most extensively studied virulence factors is a 140 kDa protein produced from a gene known as CagA (cytotoxin associated gene A) (52) . CagA is part of the pathogenicity island (PAI), a 40-kb region on the bacterial genome that encodes about 40 putative bacterial proteins. The cag PAI encodes the components of a type IV secretion system. H. pylori strains can be divided into two classes, type I and type II, based on the presence of the cag PAI (53). Yamazaki and colleagues demonstrated the presence of Cag proteins in about 60% of H. pylori isolates in Western countries and about 95% of isolates from East Asian countries (54) . CagA is associated with the inactivation of several tumor suppressor proteins, including p55 (55, 56) , and is used as a biomarker for high-risk individuals for gastric carcinoma (57, 58) .
H. pylori and HCV
Increasing evidence suggests a role for HCV co-infection in H. pylori-positive individuals. In particular, HCV is responsible for extrahepatic localizations and H. pylori plays a role in gastric dysplasia that leads to carcinogenesis (59) (60) (61) . Although, H. pylori infection of the gastric mucosa is important for the development of chronic gastritis and MALT, additional pathogenic events can accelerate malignant transformation. Studies also have linked the HCV co-infection with the development of MALT (60, 62) . Similarly, a high prevalence of H. pylori has been observed in HCV-positive patients with chronic liver disease (CLD) (63, 64) . Although the role of H. pylori in CLD and HCC progression is unclear, it has been shown that H. pylori eradication is beneficial in treating CLD and HCC patients (65) . Because both H. pylori and HCV are known to cause malignant transformation of the gastric and liver epithelium, more research is needed to understand the synergistic effects of co-infection.
H. pylori Detection, Prevention, and Treatment
In the past few decades, improvements in sanitation and hygiene have been responsible for dramatic declines in the transmission of H. pylori in industrialized countries (66) . The impact of H. pylori is particularly pronounced in countries that are transitioning from low-to high-resource economies, as adults in these populations who frequently were infected with H. pylori in childhood are now experiencing a rapid increase in life expectancy (46) .
Early prevention of infection by improving sanitary conditions and dietary modifications remains the most important tool for the prevention of H. pylori infection. Indirect measures such as immunization also have great potential for prevention but are limited by resources and costs (67) . Currently, the most effective treatment for H. pylori is a triple therapy that involves a combination of two antibiotics and a protonpump inhibitor (68) . Two antibiotics used were "amoxicillin" and "clarithromycin" and the proton-pump inhibitor was "lansoprazole."
This treatment also has been effective in promoting regression of precancerous lesions and low-grade MALT lymphomas, thereby reinforcing the need for primary prevention (69) . Antibiotic resistance is a potential problem in some individuals, however (70) . The transmission of antibiotic resistance often occurs vertically from the organism in which the mutation appears, and an increase in resistance can be observed over time (71) . H. pylori changes its genetic program which allows it to circumvent the antibiotic effect. These changes in the genetic program can be in the form of chromosomal mutations, acquisition of resistance plasmids, or through transposition of pathogenicity islands. These are the ways vertical transmission of antibiotic resistance can occur. Several studies are under way to develop antibiotic susceptibility testing methods for H. pylori strains (72, 73) .
Epstein-Barr virus
EBV is a gammaherpes virus and was the first human virus linked to cancer. EBV initially was isolated from tissue samples of BL, a rapidly growing B-cell lymphoma, in African children (74) . It is estimated that EBV infects about 90% of the world's population (27) . Primary EBV infection is acquired at a young age and involves salivary transmission of the virus to the oropharynx and probable entry through the tonsils, where the virus targets B lymphocytes for lytic and latent infection (75) . Virus bound to the surface of B-cells also can infect epithelial cells efficiently. In many developed countries including the United States, childhood EBV infections are rare (76) . EBV infections in young adults often cause the benign lymphoproliferative disease known as infectious mononucleosis. Even after the symptoms of infectious mononucleosis resolve, the virus can remain dormant or latent in the throat and blood of infected individuals, making them lifelong carriers (77) . EBV infects the squamous epithelium and the lymphoid organs, primarily B-cells of the oropharynx. In addition, the virus can reactivate periodically without symptoms and can be found in the saliva of infected individuals (76) . Most EBV-associated malignancies occur many years after infection and are associated with latent infection.
EBV-1 and EBV-2, two subtypes of EBV that infect humans, differ in their geographic distributions (78) . EBV-1 is more prevalent and is associated with 85% of nasopharyngeal carcinomas in Taiwan, whereas almost all cases of African BL are associated with EBV-2. Both EBV-1 and EBV-2 have been implicated in nasopharyngeal carcinoma and in immunocompromised individuals (76) .
Three specific patterns of viral gene expression have been associated with latent EBV infection and are identified as growth, default, and latency programs (79) . The expression patterns of the different latent genes define these latency programs (80) . The latency protein EBV-encoded nuclear antigen 1 (EBNA1) is vital for the replication of the viral genome and therefore is expressed in all types of latencies. The Latency I pattern is found in BL and gastric cancer and is restricted only to the expression of EBNA1 protein. The Latency II pattern expresses the EBV-encoded RNAs (EBERs), BamHI-A rightward transcripts (BARTs), EBNA1 protein, and the latent membrane proteins (LMP1, LMP2A, and LMP2B), and is associated with Hodgkin lymphoma and nasopharyngeal cancer. The Latency III pattern expresses both EBERs and BARTs and all of the EBV latent proteins-the 6 nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA-LP) and 3 membrane proteins (LMP1, LMP2A, and LMP2B), which are characteristics of lymphoblastoid cell lines and post-transplant lymphoproliferative disease. Although B-cell malignancies have the potential to support any of the three latency programs, non-B-cells generally display either a Latency I or Latency II type of infection.
EBV is classified as a carcinogen and is the causative agent for several malignant tumors, including B-cell neoplasms such as BL and Hodgkin lymphoma, certain forms of T-cell lymphoma, nasopharyngeal carcinoma, and certain types of gastric cancers (81) . EBV has been found to be significantly associated with undifferentiated nasopharyngeal cancer, regardless of geographic location (82) . The virus infects the epithelial cells of the posterior nasopharynx in Rosenmüller's fossa in Waldeyer's ring. Undifferentiated nasopharyngeal cancer is prevalent in Hong Kong and Taiwan, and in the Inuits in Alaska and Greenland. In Taiwan, nasopharyngeal carcinoma is the most common cancer in men and the third most common in women (83) .
One common aspect of EBV-associated cancers is the presence of multiple extrachromosomal copies of the circular viral genome (EBV episomes) in the tumor cells (84) . The EBV genome contains more than 100 genes that regulate the expression of EBV-encoded latency proteins such as EBNA-1, which is needed for the replication of EBV episomes (85) . Because EBV-associated lymphoproliferative diseases are primarily associated with viral latency, many aspects of the latent antigens have been studied extensively. Transformation by EBV involves several latency gene products such as EBNA1, EBNA2, EBNA3, and LMP1, which are known to contribute to malignant phenotypes (86) . These EBV proteins mimic several growth, transcription, and antiapoptotic factors and disrupt cellular homeostasis (76) . EBV-associated malignancies develop years after primary EBV infection, and these tumors often initiate from a clone of EBV-infected cells (87) .
Several recent studies have shown an association between EBV and gastric carcinoma as well (88) (89) (90) . The presence of EBV varies from about 90% in lymphoepithelioma-like gastric carcinomas to between 5% and 25% in gastric adenocarcinomas (91, 92) . EBV-associated gastric carcinoma is monoclonal, belongs to the Latency I program, and displays a characteristic pattern of global and nonrandom CpG island methylation in the promoter region of cancer-related genes. Because the viral genes also are regulated by promoter methylation in the infected cells, the DNA methylation mechanism specific to EBV-associated gastric carcinoma may be a perturbation of the primary defense system against foreign DNA (92) .
The EBV genome is clonal and found as an episome in infected individuals. The EBV-transforming protein LMP1 is expressed in all HIV-associated Hodgkin lymphoma cases (20) . Some studies have reported that LMP1 mimics the CD40 receptor and hence activates the NFκB pathway, thereby preventing apoptosis in the Reed-Sternberg cells (93) . The development of highly active antiretroviral therapy (HAART) has reduced AIDS-related opportunistic infections in HIV-positive Hodgkin lymphoma patients and prolonged survival (94) .
EBV and P. falciparum
BL is a highly aggressive type of B-cell lymphoma (81) . There are two types of BL: endemic and sporadic. Endemic BL (eBL) has a 95% association with EBV infection and accounts for 50% of childhood malignancies in equatorial Africa. eBL often is linked to co-infection with malaria-causing P. falciparum (22) . Identifying the specific role of malaria in EBV-associated BL has been challenging, and several mechanisms have been proposed to elucidate this association (15, 22, 95) . It is hypothesized that the immunomodulatory effects of malarial infection can cause expansion of EBVpositive B lymphocytes, leading to eBL incidence (96) . during P. falciparum infection, leading to enhanced EBV replication (97) . An association between antimalarial treatment in holoendemic areas and a decrease in eBL incidence has been reported, although these studies have not been conclusive (15) . Other studies have suggested that the timing and duration of P. falciparum co-infections may be important for eBL pathogenesis because the incidence of eBL is highest in children between 4 and 9 years of age, which follows the age group for highest incidence of P. falciparum-mediated malaria (15, 22) . Infection with plasmodium is mitogenic to B-cells and causes hypergammaglobulinemia (98) . Further, children with acute malaria have a significantly higher number of peripheral B-cells (99) . Hence, there is a need to better understand the role of plasmodium co-infection in eBL occurrence (100) . The incidence of sporadic BL increases significantly, however, when associated with HIV infection. Despite its fast-growing and life-threatening nature, BL is a more curable form of lymphoma. BL treatment has a success rate of almost 80%, with rare occurrences of late relapses (81) . There is a chromosomal rearrangement between one of the immunoglobulin heavy or light chain promoters or enhancers and the c-MYC proto-oncogene in almost all BLs, and this translocation results in deregulated c-MYC expression and neoplastic transformation of B-cells (11) .
P. falciparum induces B-cell expansion and lytic EBV reactivation, causing expansion of EBV-infected B-cells. Other reports have highlighted that T-cell immunity is impaired

EBV and HIV
EBV infection attributes to 50% of Hodgkin lymphoma cases in the United States (76) . Hodgkin disease is characterized by the expansion of cells of the B-lineage called Reed-Sternberg cells. Studies have shown that the incidence of EBV-positive Hodgkin lymphoma is age-related and is preferentially associated with pediatric and older patients (101) . The EBV incidence rate for Hodgkin lymphoma increases to about 95% in AIDS patients (102) . Interestingly, HIV-associated Hodgkin lymphoma has an aggressive clinical behavior and is associated with a poor prognosis (93) . The pathological spectrum of HIV-associated Hodgkin lymphoma is unique and includes mixed cellularity and lymphocyte depletion, and the tumor tissue is characterized by a large proportion of neoplastic Reed-Sternberg cells (20) . Patients with non-HIV-associated Hodgkin lymphoma have a low population of Reed-Sternberg cells.
EBV and HPV
Recent studies have examined the association between EBV and high-risk strains of HPV in the progression of human oral cancers (103, 104) . EBV and HPV DNA have been detected in nasopharyngeal carcinoma samples, which suggests that EBV and HPV co-infections could be involved in the neoplastic transformation of the oral epithelium (105) (106) (107) . Other studies have detected EBV and HPV co-infections in head and neck carcinomas and in HIV-positive oral hairy leukoplakia patients (108, 109) . Although it has been established that approximately 38% of human nasopharyngeal carcinomas are associated with high-risk HPV and EBV co-infections, the mechanism of carcinogenesis is not yet understood. Some studies hypothesize that HPV oncoproteins E6/E7 cooperate with the EBNA1, LMP1, LMP2, and BARF1 EBV oncoproteins to transform the oral epithelium (103) . Additional studies are needed to explore the role and pathogenesis of HPV and EBV co-infection in human nasopharyngeal carcinogenesis.
EBV Detection, Prevention, and Treatment
The high prevalence of EBV, its easy mode of transmission, and a lack of understanding of the triggers that lead to EBVassociated cancer complicate the development of targeted prevention strategies (81, 110) . In addition, even after clearance of primary infection, EBV can persist as an episome in infected B-cells, thereby establishing latent infection (84) . Currently, broad-spectrum antiviral agents and immunebased therapies, including specific monoclonal antibodies, have shown promise in the treatment and management of EBV-related lymphoproliferative disorders (111) (Table III) .
Although the role of latent EBV antigens in carcinogenesis has been studied extensively, a better understanding of the genetic regulation and molecular mechanisms of EBV-linked lymphoproliferative malignancy infection is essential for the development of novel therapies (112, 113) . Because prophylactic vaccines are safe and effective public health intervention strategies, the National Institutes of Health has provided guidelines for future EBV vaccine development that focus on disease prevention facilitated by the identification of diseasepredictive surrogate markers, rather than on infection (114) .
Human Papillomaviruses (HPVs)
HPVs are small DNA viruses that are found in the squamous epithelium of the genital tract (115). Studies have established HPV as a necessary cause of cervical cancer (14, 116, 117) , the second most common cancer in women worldwide. It is estimated that HPV is responsible for about 5% of the global cancer burden (118) . The prevalence of HPV infection varies geographically, with a nearly 20-fold difference in infection rates (119) . Variance also occurs in HPV types among populations (120) . The disproportionate burden of HPV-associated cancer experienced in developing countries is highlighted by the fact that more than 85% of cervical cancer diagnoses and deaths occur in developing countries (121) .
Thus far, more than 100 HPV types have been identified, of which about 40 strains are categorized as oncogenic and 15 as high-risk serotypes (119) . Almost all cervical cancers are caused by persistent infection of high-risk HPV serotypes that are genetically related to HPV-16 and HPV-18 (122) . In fact, HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancers and a high percentage of anogenital and oropharyngeal carcinomas (123) . Although the probability of acquiring a cervical infection with HPV is about 80% for sexually active individuals, most infections clear spontaneously (124) . The percentage of infected individuals who develop low-to high-grade squamous intraepithelial lesions is very low. In individuals with high-grade lesions, additional factors such as immunosuppression, smoking, multiparity, and co-infection with herpes simplex virus, chlamydia, HIV, or other strains of HPV can tilt the balance to cancer progression (12, 125) . Because HPV is transmitted sexually, studies have shown that multiple sexual partners significantly increase the risk of HPV infection (14) .
In addition to its causal role in cervical cancer, HPV has been associated with many noncervical cancers, based on clinical and epidemiologic evidence (126) . HPV infection also has been associated with a subset of anal, oropharyngeal, vulvar, vaginal, and penile cancers (127, 128) . Furthermore, in the industrialized world, increased incidence of noncervical HPV-related cancers, especially head and neck cancers, has been observed (128) . Although cervical cancer incidence rates have declined significantly in the United States in recent years, the incidence rates for anal, oropharyngeal, and vulvar cancers have increased greatly (127) . Men are three times more likely than women to develop head and neck cancers. By 2020 in the United States, more cases of oral HPV-positive cancers among men are expected than cervical cancer among women (129) . Approximately 80% to 90% of the HPV-associated noncervical cancers are caused by HPV 16 and 18 (129) .
HPV carcinogenesis is correlated with the ability of the virus to integrate into the host genome, as cancer in the absence of integration is very rare (130) . The mechanism of HPV integration into the host genome is not completely understood, but several studies have suggested that host DNA damage may play a significant role (13, 130, 131) . Host integration of HPV results in the increased expression of several viral oncogenes, including E6 and E7, that are primarily responsible for transformation (132, 133) . After integration, these oncogenes are transcribed in the cancer cells, and inhibition of these genes can reverse the carcinogenic process. Although the retinoblastoma proteins (Rb) and p53 are known targets for the HPV E6 and E7 oncoproteins, recent studies have identified other cellular targets, including telomerase, signaling proteins, and members of the DNA damage pathway (133) .
Chlamydia Trachomatis (CT) and HPV
CT is a gram-negative, obligate intracellular bacterium with a dimorphic life cycle and is one of the most common sexually transmitted agents (134) . The correlation between HPV and CT co-infection and cervical neoplasia has been studied using case-control studies (135) (136) (137) (138) . Although the mechanism by which CT induces cervical neoplasia is unknown, two theories have been proposed for its role as a risk factor in HPV-associated cervical cancer (139, 140) . Whereas some studies have shown that CT infection increases the susceptibility for HPV uptake (141) , others have highlighted its role in increasing HPV infection persistence (142, 143) , thereby leading to cervical metaplasia. Increased levels of CT DNA or IgG antibodies were found in HPV-infected women, suggesting a common route for transmission and co-infection (144) .
The identification of novel immune evasion strategies and the analysis of their functions in the context of bacterial and viral infections may lead to a better understanding of the immune system and its interaction with these pathogens (145) . An important area for research is implementing large-scale screening for CT and studying its role in affecting the efficacy of HPV vaccines and cervical cancer prevention.
HPV and HIV
Decreased cell-mediated immunity is an important risk factor for HPV infection leading to cervical neoplasia and cancer (146) . Several studies have shown an increased association between HPV co-infection and cervical neoplasia in HIVpositive women (147, 148) . Also, HIV-positive women with severe immunosuppression have twice the risk of developing cervical cancer (149) . Interestingly, in Africa, where both HIV and HPV infections are endemic, studies have found no increase in invasive cervical neoplasia among HIV-positive women (150, 151) . Sun and colleagues (146) suggested that HIV-positive women have a higher chance of being infected with multiple HPV types, including high oncogenic types such as HPV-16 and -18. The, U.S. Public Health Service and Centers for Disease Control and Prevention have recommended that HIV-positive women undergo 2 Pap tests, 6 months apart, following the initial diagnosis of HIV infection (152) . Although studies have shown that HPV co-infection in HIV-positive women increases the risk of HPV-related neoplasms of the cervix, vulva, and anus, a corresponding risk of invasive cervical cancer has not yet been demonstrated. More studies are needed to address this topic and to provide effective treatment and prevention options.
Multiple HPV Infections
Until recently, the effect of co-infection with more than one HPV type on cervical cancer causation and progress had not been studied. Epidemiologic studies have, however, addressed the effect of co-infections with multiple HPV types on cervical cancer (117, 153, 154) . These studies have shown that multiple HPV infections commonly occur in individuals who have not had any treatment for HPV infection (155, 156) . Co-infection with multiple types of HPV can be a risk factor due to increased HPV persistence that can lead to invasive cervical lesions (154, 155) . Lastly, patients with multiple HPV infections have been found to have large tumor size, increased susceptibility to cervical cancer, and decreased response to cancer treatment (154, 155) . One potential problem is that the use of HPV vaccines could alter the distribution of other HPV types. Further surveillance studies are needed to determine whether a distribution shift will be seen in individuals who are co-infected with HPV.
HPV Detection, Prevention, and Treatment
HPV detection is accomplished using immunology, serology, or molecular biology techniques (113, 157) . Studies have shown that implementing routine screening programs, such as those involving Pap tests and visual exams for women, can be an effective approach in preventing cervical cancer (129, 158) . The incidence of cervical cancer in the United States was significantly reduced as a result of cervical cancer screening programs that enabled the detection and treatment of precancerous lesions (39) . Prevention strategies for HPV-associated cervical cancer have included screening and vaccination (Table III) . Widespread implementation of cervical cancer screening programs in low-resource settings has been limited by cost; however, the recent development and validation of relatively inexpensive HPV-based tests make screening programs cost-effective. Vaccines also can provide an opportunity for the prevention of HPV-associated cancers. Based on evidence that persistent HPV infection and premalignant anogenital cancer can be prevented, the U.S. Food and Drug Administration approved two HPV vaccines made of noninfectious subunits of the viral L1 major capsid protein (129) . This vaccine (Gardasil) is recommended for females 9 to 26 years of age and is administered intramuscularly on a 3-dose schedule (159, 160) . Although HPV vaccine research has been centered on the vaccine's ability to prevent cervical cancer in women, demand is increasing for using the vaccine in men to prevent genital warts and anal cancer (161) .
Hepatitis Viruses
Liver cancer, primarily HCC, is the fifth most common cancer and the third leading cause of cancer deaths worldwide (162) . Chronic infections with either HBV or HCV have been associated with about 80% of HCCs (163) . Both HBV and HCV have been categorized by the IARC as human carcinogens (164) . The individual risk of HCC increases by 22% and 17%, respectively, for HBV and HCV infections (165) .
The World Health Organization (WHO) estimated that 2 billion people worldwide had been infected with HBV, and about 350 million were living with chronic HBV infection (166) . The prevalence of HBV and HCV infection varies significantly by region. Rates of HBV infection are highest in Africa and Asia, with 12% or more of the populations in China and in most parts of Africa testing positive for the virus, compared with less than 1% of the populations in Western and Northern Europe and North America (2) . Rates of HCV infection are high in Egypt (15%), Pakistan (4.8%), and China (3.2%) although HCV is found worldwide (http:// www.who.int/mediacentre/factsheets/fs164/en/). More than 80% of HCC cases occur in developing countries in Southeast Asia, East Asia, and Sub-Saharan Africa (167) .
Both HBV and HCV are transmitted through exposure to bodily fluids (i.e., semen and blood) and can cause acute or chronic liver disease and cancer (168, 169) . Factors that contribute to hepatitis-mediated HCC risk include excessive alcohol intake, non-alcoholic steatohepatitis (which is associated with obesity and metabolic syndrome), HIV-associated immunodeficiency, and exposure to aflatoxins (167, 170) .
Although HBV and HCV cause hepatotropic viral infections, they differ taxonomically and have distinct life cycles and oncogenic mechanisms. HBV is a DNA virus of the Hepadnaviridae family that can directly integrate into host DNA and transform hepatocytes (171) . HBV DNA is integrated into the host cellular DNA in approximately 90% of HBV-positive liver cancers (172) . HCV is an RNA virus from the Flaviviridae family that cannot integrate into the host genome and causes HCC by various indirect mechanisms (173) . The HCV viral proteins have been shown to affect cellular pathways by upregulating oncogenes and altering tumor-suppressor genes, thereby leading to hepatocarcinogenesis (174) . Both HBV and HCV infections cause hepatocyte injury and chronic inflammation, leading to fibrosis, cirrhosis, and HCC (175) .
HCC is a highly heterogeneous tumor and involves a number of genetic and epigenetic alterations, resulting in aberrations in multiple signal transduction pathways (171, 175) . Studies have demonstrated that inflammatory responses to HBV and HCV infections, destruction and regeneration of hepatocytes, and activation of viral proteins contribute to hepatocyte transformation (167, 176) . In addition, HBV, HCV, and HIV have similar transmission routes, leading to high co-infection rates and synergistic interaction between the viruses during HCC progression (177) (178) (179) .
HBV and HCV
Co-infection with HBV and HCV is common in high-endemic areas such as Southeast-Asia and Mediterranean regions (31) . HBV and HCV co-infections often are found in persons with chronic liver diseases, injection drug users, and HIV-positive individuals (179) . The interaction between HBV and HCV in co-infected individuals has been investigated in clinical studies (30, (180) (181) (182) (183) . Some studies have described suppression of HBV replication by HCV in acutely or chronically infected patients (183) (184) (185) . Recent studies have identified HCV core protein as a repressor of HBV production and replication (186, 187) . The combined effect of HBV and HCV on HCC remains unclear, however. Although epidemiologic studies have highlighted the superadditive effect of co-infection with HBV and HCV on increasing the risk for HCC (165, 188, 189) , other studies have reported a subadditive effect on dual infection (32) . Similarly, it has been suggested that latent HBV infection plays an important role in carcinogenesis in HCV-infected individuals (190, 191) . HCV is not directly cytopathic, and the pathogenesis of liver injury is believed to be immune mediated. Therefore, more studies are needed that identify the mechanism of interaction between HBV and HCV and their effect on HCC.
HBV and HDV
Hepatitis δ virus (HDV) was first identified in 1977 in patients with a more severe form of HBV infection (192) as a blood-borne single-stranded RNA virus. Although the HDV genome can replicate independently, HDV is dependent on HBV to complete its life cycle. HDV utilizes the envelope proteins of HBV to assemble virus particles for new rounds of infection (193) . Studies have shown that HDV infection often occurs as a superinfection in HBV patients and increases the risk of hepatitis and liver damage (194, 195) . It still is unclear whether super-or co-infection of HDV in HBV-positive individuals increases the relative risk for HCC.
Recently, there has been increased interest in understanding the mechanism of HDV replication to enable development of new antiviral strategies. Because HBV vaccination also will protect against HDV, it currently is the most effective prevention strategy. Chronic HDV infections are treated by extensive alpha-interferon therapy and antivirals (196) .
Aspergillus and the Hepatitis Virus
In many low-income countries, contamination of food with aflatoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus is an important contributor to HCC, especially in patients with chronic hepatitis (197, 198) . Aflatoxins are naturally occurring secondary metabolites of food-borne fungi that are common contaminants present in stored grains in the subtropical regions of the world (199) .
Aflatoxin contamination contributes to about 28% of HCC worldwide. There are about 20 aflatoxins, of which Aflatoxin B1 (AFB1)-the product of the common mold Aspergillus flavus-is the most potent (200) . The IARC has identified AFB1 as a chemical liver carcinogen (201) . Aflatoxin has been implicated in the development of HCC, especially in individuals with either HBV or HCV infection (200) . Liu and colleagues extensively assessed the global burden of aflatoxin-induced HCC and estimated that the biggest burden of aflatoxin is in Sub-Saharan Africa, Southeast Asia, and China (197) . Although aflatoxin is an easily preventable risk factor, limited resources to implement aflatoxin control strategies result in higher exposure rates in developing countries (198) . Intervention strategies to prevent aflatoxin exposures can be grouped into three categories: agricultural, dietary, and clinical (202) . These include pre-and post-harvest strategies to prevent mold in food grains, reducing aflatoxin-related illness, and HBV vaccination in high-risk populations. The assessment of exposure to aflatoxin has evolved with the characterization of biomarkers such as aflatoxin-albumin adducts in serum and aflatoxin-N7-guanine in urine (203) .
HIV and the Hepatitis Virus
Co-infection with HBV and HCV are very common in HIV patients (167) . In the United States, it is estimated that 25% of HIV patients are infected with HCV, and 7%-10% are infected with HBV as well (204, 205) . The prevalence of HCV in HIV patients who acquire infection through intravenous drug abuse or multiple blood transfusions is 75%-90% (24, 206) . Co-infection by HCV and HBV in HIV-positive individuals is common because these viruses share similar modes of transmission (167) . In HIV patients undergoing HAART treatment with longer survival rates, HCC due to HCV and HBV infections is a significant problem (21) . Although there is evidence of a cytopathic effect of HIV on liver tissue, HIV co-infection with HBV or HCV can cause a severe progression to HCC-related mortality (180, 181) . Further, the treatment response in co-infected patients is significantly lower, with the 5-year survival rate decreasing from 72% in mono-infected individuals to 33% in co-infected individuals (204) . The interaction between HBV/HCV and HIV and its impact on liver injury is unclear. The pathogenesis of HBV and HCV liver injury in HIV patients is immunemediated because the CD4 T-cell responses are reduced (207, 208) . A better understanding of liver disease in co-infected patients is needed to develop new strategies for improving outcome and survival.
Hepatitis Virus Detection, Prevention, and Treatment
Vaccines are available and effective in preventing HBV infection (Table III) . Many countries have developed universal HBV-vaccination strategies with high success rates (38). In Taiwan, universal HBV vaccination has almost eradicated HBV-related pediatric liver cancer (209) . Currently, there is no vaccine available for HCV, and interferon treatment is effective in clearing acute HCV infections in only about onethird of patients (210) . Hence, screening and treatment for HCV infection in high-risk populations such as intravenous drug users, among whom the prevalence of HCV infection is about 90%, is an important strategy for the prevention of HCV-mediated HCC (171) . 
Mechanisms of Carcinogenesis
The discovery and study of cancer-causing infections have provided key insights into the cellular mechanisms of cancer. Chronic infections can cause cancer through a complex process that involves an interplay between the pathogen and host (38). The process of cancer initiation is affected by biological factors that include age, race, and gender; behavioral factors such as smoking, diet, exercise, and alcohol consumption in the host; and environmental factors (4, 211, 212) . Because each cancer is linked to several risk factors, removal of a single risk factor often does not lead to cancer prevention. Hence, primary prevention of the infection is crucial for cancer prevention (213).
The events leading from a pathogenic infection to carcinogenesis can be multifaceted, including chronic inflammation, impairment of the host immune system, modulation of cell proliferation and survival pathways, and genomic instability (215) . Malignant transformation of the host often occurs as a result of genome instability, which is an important event in carcinogenesis (45) . Most cancer-associated infectious agents, including viruses, bacteria, and parasites, are broadly divided into two categories: indirect and direct carcinogens. Indirect carcinogens cause cancer through chronic infection and inflammation that leads to carcinogenic mutations of the host cells. H. pylori infection is an example of indirect carcinogenesis mediated by chronic inflammation (216) . Chronic inflammation that results in prolonged exposure to inflammatory mediators such as free radicals, prostaglandins, and cytokines can cause DNA damage and oncogenic mutations in the host (214) . During indirect oncogenesis, the mechanism of host transformation is variable, and oncogenic genes are lost as tumors mature. As a result, it is difficult to establish causality for host transformation in indirect carcinogenesis.
In contrast, oncogenic viruses such as HPV and EBV are considered direct carcinogens because they express viral oncogenes that can directly transform host cells. During direct oncogenesis, some of or the whole viral genome integrates with the host genome and modifies the proliferation and survival pathways within the host cell, thus causing cancer (215, 216) . It also is interesting that one infectious agent requires another for survival, as seen in the case of HDV, which requires HBV to complete its life cycle (192, 193, 196, 197) . However, the exact role of double (HBV with HDV) and triple (HBV, HCV, and HDV) infections in mediating HCC is yet to be understood completely (30, 217) .
Research at the National Cancer Institute
The National Cancer Institute (NCI) supports numerous projects aimed at identifying key determinants of cancer risks caused by infectious agents. These projects include epidemiologic, biologic, genetic, and clinical research, as well as training and research capacity building. Some of these grants foster international collaborations, including large-scale clinical and cohort studies in Central America, Africa, Europe, Canada, and Asia.
The prevention of infection-related cancers would have a tremendous impact on reducing the global cancer burden. Research questions remain concerning the primary prevention of cancers associated with infectious agents, but the keys to unraveling the role of co-infection as a risk factor are within our scientific reach. Table IV highlights some of the unanswered research questions. • Are there specific risk factors and biomarkers for different racial and ethnic groups that make them especially high-risk populations for cancers associated with infectious agents? Can these biomarkers be utilized for targeted therapeutics? • With efforts to eradicate pathogens for disease prevention under way, what is the significance of H. pylori colonization and co-evolution in humans, and what are the implications for other infectious diseases? • Infections with certain agents such as H. pylori have been suggested to decrease the risk of some cancers, including esophageal adenocarcinomas.
Can we use information from the human microbiome to better understand this effect and develop mechanisms to improve prevention and treatment of malignant infections? • Can we utilize our understanding of the natural history of infectious agents in causing cancer and determinants of these patterns to develop effective prevention and treatment mechanisms? How can we effectively translate epidemiologic data to help improve our understanding of cancer etiology? • Some infectious agents are attributed to the development of more than one cancer-e.g., EBV and BL, nasopharyngeal carcinoma, and gastric cancer.
What are the viral and host factors that predispose an individual to cancer development? Are there different EBV variants with differential carcinogenic potential? Are there distinct immunologic response profiles that protect or predispose EBV-infected individuals to cancer development? Does the timing of initial EBV infection determine whether protective or permissive infections/immune responses occur? • How does the increasing frequency of obesity and diabetes mellitus affect the incidence of HCC in developing countries with a high prevalence of HBV and/or HCV infection? • Why does HDV require HBV to complete its life cycle? Why are HIV patients more susceptible to HBV/HCV infections than to other infectious agents?
How can we effectively target cancer cells/infectious agents and maintain harm reduction in the host? • How can we effectively develop new studies to better understand the antigenic camouflage of an oncovirus to prevent antigenic evasion? • How can we better position ourselves to develop successful prevention strategies against current and new oncoviruses so that we ultimately can prevent infection and subsequent carcinogenesis? Currently, most NCI-funded projects on co-infections focus on HIV-and AIDS-related malignancies. NCI researchers are investigating mucosal immunization against HPV in collaboration with researchers at the Universitaire Vaudois in Switzerland and are evaluating the use of live, attenuated measles virus vectors as delivery vehicles for HPV prophylactic vaccines in collaboration with Etna Biotech in Italy. Researchers at the Center for Cancer Research's (CCR) Basic Research Laboratory and Laboratory of Experimental Immunology are using targeted and genome-wide association studies (GWAS) to identify host genetic factors associated with susceptibility to and pathogenic outcomes of HBV and HCV infection. Laboratory of Experimental Immunology researchers have identified a human leucocyte antigen (HLA) genotype that is associated with low baseline HCV load and low odds of liver fibrosis among individuals infected with both HCV and HIV.
Perspectives and Conclusions
In this review, we have highlighted studies on infectious agents that have been associated with cancer etiology. Multiparasitism and co-infections are common in developing countries where malignant infections are endemic. Despite the implication of co-infections as a risk factor for cancer, the relative risks of single versus multiple infections for specific cancer types have yet to be estimated (32, 140, 156, 217) . Studies exploring the effects of single and multiple infections on a specific cancer often have design limitations and yield incomplete information (15, 59, 205, 206) . Because multiple infections can cause a single cancer via different biological pathways, estimating the contribution of any individual agent is challenging and requires complex epidemiologic methods (6, 221) .
Further, while some malignant infections have a protective effect on certain types of cancer, superinfection with one agent sometimes suppresses the effect of another infectious agent (222, 223) . The factors that contribute to cancer initiation and progression during co-infections and multiparasitism therefore remain controversial. Although the vertical transfer of an infectious agent from mother to child can lead to childhood cancer, the role of co-infections in early childhood is debatable. zur Hausen (2009) highlighted the protective effect of multiple infections during early childhood and postulated that the absence of widespread viral infection can be a risk factor for certain infection-related malignancies (218) .
Detection and prevention of co-infections is hampered by a lack of broad-spectrum diagnostic tools and integration of control interventions. Hence, there is a need for systemic analysis and better epidemiologic tools to gain insight into the role of co-infections in cancer. A detailed understanding of the risk factors will enable better targeting of new strategies for the early detection, prevention, and treatment of infection-associated cancers.
